The thymus and myasthenia gravis: Immunological and neurophysiological aspects

Annals of Medicine

Volumn 31, Issue SUPPL. 2, 1999, Pages 52-56

  Carrieri, Pietro B ^a   Marano, Enrico ^a   Perretti, Anna ^a   Caruso, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cytokines; Electromyography; Myasthenia gravis; Thymus

Indexed keywords

ALPHA INTERFERON; CHOLINERGIC RECEPTOR ANTIBODY; CYTOKINE; NICOTINIC RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

AUTOIMMUNE DISEASE; CONFERENCE PAPER; ELECTROMYOGRAPHY; HUMAN; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NEUROPHYSIOLOGY; PRIORITY JOURNAL; THYMUS;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; ELECTROMYOGRAPHY; ELECTROPHYSIOLOGY; FEMALE; HUMANS; MALE; MYASTHENIA GRAVIS; SEX FACTORS; THYMUS GLAND;

EID: 0032755411     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Robertson NP, Deans J, Compston DAS. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry 1998; 65: 492-6.
2. Wekerle H. The thymus in myasthenia gravis. Ann N Y Acad Sci 1993; 681: 47-55.
3. Wheatley LM, Urso D, Zheng Y, Loh E, Levinson AI. Molecular analysis of intrathymic nicotinic acetylcholine receptor. Ann N Y Acad Sci 1993; 681: 74-82.
4. Hohlfeld R, Kalies I, Kohleisen B, Heininger K, Conti-Tronconi BM, Toyka KV. Myasthenia gravis: stimulation of antireceptor autoantibodies by autoreactive T cell lines. Neurology 1986; 36: 618-21.
5. Conti-Fine BM, Navaneetham D, Karachunski PI, Raju R, Diethelm-Okita B, Okita D, et al. T cell recognition of the acetylcholine receptor in myasthenia gravis. Ann N Y Acad Sci 1998; 843: 283-308.
6. Shiono H, Fujii Y, Okumura M, Takeuchi Y, Inoue M, Matsuda H. Failure to down-regulate Bcl-2 protein in thymic germinal center B cells in myasthenia gravis. Eur J Immunol 1997; 27: 805-9.
7. Masunaga A, Aiai T, Yoshitake T, Itoyama S, Sugawara I. Reduced expression of apoptosis-related antigens in thymuses from patients with myasthenia gravis. Immunol Lett 1994; 39: 169-72.
8. Graus YF, de Baets MH, Burton DR. Antiacetylcholine receptor Fab fragments isolated from thymus-derived phage display library from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. Ann N Y Acad Sci 1998; 841: 414-7.
9. Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330: 1797-810.
10. Marano E, Pagano G, Persico G, Striano S, Buscaino GA, Campanella G. Thymectomy for myasthenia gravis: predictive factors and long term evolution. A retrospective study on 46 patients. Acta Neurol (Napoli) 1993; 15: 277-88.
11. Wekerle H, Ketelson U-P, Zurn AD, Fulpius BW. Intrathymic pathogenesis of myasthenia gravis: transient expression of acetylcholine receptors on thymus-derived myogenic cells. Eur J Immunol 1978; 8: 579-82.
12. Schluep M, Willcox N, Vincent A, Dhoot GK, Newsom-Davis J. Acetylcholine in human thymic myoid cells in situ: an immunologic study. Ann Neurol 1987; 22: 212-22.
13. Moulian N, Wakkach A, Guyon T, Poea S, Aissaoui A, Levasseur P, et al. Respective role of thymus and muscle in autoimmune myasthenia gravis. Ann N Y Acad Sci 1998; 843: 397-406.
14. Emilie D, Crevon MC, Cohen-Kaminski S, Peuchmaur M, Devergne O, Berrih-Aknin S, et al. In situ production of interleukins in hyperplastic thymus from myasthenia gravis patients. Hum Pathol 1991; 22: 461-8.
15. Schonbeck S, Padberg F, Marx A, Hohlfeld R, Wekerle H. Transplantation of myasthenia gravis thymus to SCID mice. Ann N Y Acad Sci 1993; 681: 66-73.
16. Truffault F, Cohen-Kaminsky S, Khalil I, Levasseur P, Berrih-Aknin S. Altered intrathymic T-cell repertoire in human myasthenia gravis. Ann Neurol 1997; 41: 731-41.
17. Marx A, Schultz A, Wilisch A, Helmreich M, Nenninger R, Muller-Hermelink HK. Paraneoplastic autoimmunity in thymus tumors. Dev Immunol 1998; 6: 129-40.
18. Muller-Hermelink HK, Marx A, Geuder K, Kirchner T. The pathological basis of thymoma-associated myasthenia gravis. Ann N Y Acad Sci 1993; 681: 56-65.
19. Barchan D, Asher O, Tzartos SJ, Fuchs S, Souroujon MC. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor. Eur J Immunol 1998; 28: 616-24.
20. Zhang J, Zhou WB, Wang HL, Guo SS. The effects of T cell subpopulations and recombinant interleukin-2 on peripheral B cell function in patients with myasthenia gravis. Hum Antibodies 1997, 8: 90-4.
21. Tzartos SJ, Kokla A, Walgrave SL, Conti-Tronconi BM. Localization of the main immunogenic region of human acetylcholine receptor to residues 67-76 of the alpha subunit. Proc Natl Acad Sci U S A 1988; 85: 2899-903.
22. Wang ZY, Okita DK, Howard JF Jr, Conti-Fine BM. Th1 epitope repertoire on the alpha subunit of human muscle acetylcholine receptor in myasthenia gravis. Neurology 1997; 48: 1643-53.
23. Nagvekar N, Moody AM, Moss P, Roxanis I, Curnow J, Beeson D, et al. Pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4-producing T cell clones recognizing extracellular acetylcholine receptor presented by minority class II isotypes. J Clin Invest 1998; 101: 2268-77.
24. Moiola L, Protti MP, McCormick D, Howard JF Jr, Conti-Tronconi BM. Myasthenia gravis. Residues of the alpha and gamma subunits of the muscle acetylcholine receptor involved in formation of immunodominant CD4+ epitopes. J Immunol 1994; 152: 4686-98.
25. Schonbeck S, Chrestel S, Hohlfeld R. Myasthenia gravis: prototype of antireceptor autoimmune diseases. Int Rev Neurobiol 1990; 32: 175-200.
26. Protti MP, Manfredi AA, Horton RM, Bellone M, Conti-Tronconi BM. Myasthenia gravis: recognition of a human autoantigen at the molecular level. Immunol Today 1993; 14: 363-8.
27. Morgutti M, Conti-Tronconi BM, Sghirlanzoni A, Clementi F. Cellular immune response to acetylcholine receptor in myasthenia gravis: thymectomy and corticosteroid. Neurology 1979; 29: 734-8.
28. Ahlberg R, Yi Q, Pirskanen R, Matell G, Swerup C, Rieber EP. Treatment of myasthenia gravis with anti-CD4+ antibody: improvement correlates to decreased T-cell autoreactivity. Neurology 1994; 44: 1732-7.
29. Moiola L, Protti MP, Manfredi AA, Yuen MH, Howard JF Jr, Conti-Tronconi BM. T-helper epitopes on human nicotinic acetylcholine receptor in myasthenia gravis. Ann N Y Acad Sci 1993; 681: 198-218.
30. Wang ZY, Okita DK, Howard JF Jr, Conti-Fine BM. T-cell recognition of muscle acetylcholine receptor subunits in generalized and ocular myasthenia gravis. Neurology 1998; 50: 1045-54.
31. Ragheb S, Lisak RP. The immunopathogenesis of acquired (autoimmune) myasthenia gravis. In: Lisak RP, ed. Handbook of Myasthenia Gravis and Myasthenic Syndromes. New York: Dekker; 1994; 239-76.
32. Zhang J, Zhou WB, Wang HL, Guo SS. The effects of T cell subpopulations and recombinant interleukin-2 on peripheral B cell function in patients with myasthenia gravis. Hum Antibodies 1997; 8: 90-4.
33. Carrieri PB, Provitera V, De Rosa T, Tartaglia G, Gorga F, Perrella O. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis. A correlation with clinical activity. Immunopharmacol Immunotoxicol 1998; 20: 373-82.
34. Zhang G-X, Navikas V, Link H. Cytokines and the pathogenesis of myasthenia gravis. Muscle Nerve 1997; 20: 543-51.
35. Ahlberg RE, Pirskanen R, Lefvert AK. Defective T lymphocyte function in nonthymectomized patients with myasthenia gravis. Clin Immunol Immunopathol 1991; 60: 93-105.
36. Link J, Navikas V, Fredrikson S, Osterman PO, Link H. Augmented IFN-gamma, IL-4 and TGF-beta mRNA expression in blood monuclear cells in myasthenia gravis. J Neuroimmunol 1994; 51: 185-92.
37. Link J, He B, Navikas V, Fredrikson S, Link H. Transforming growth factor-beta-1 suppresses autoantigen-induced expression of pro-inflammatory cytokines but not interleukin-10 in multiple sclerosis and myasthenia gravis. J Neuroimmunol 1995; 58: 21-35.
38. Hartung HP, Reiners K, Schmidt B, Stoll G, Toyka KV. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculopathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 1991; 30: 48-53.
39. Weissert R, Melms A, Link H. Altered tumor growth factor beta mRNA expression is associated with thymectomy-related clinical remission in myasthenia gravis. J Neurol Sci 1997; 151: 49-55.
40. Ahlberg R, Yi Q, Pirskanen R, Matell G, Sundevall AC, Aberg B, et al. The effect of thymectomy on autoreactive T- and B-lymphocytes in myasthenia gravis. J Neuroimmunol 1997; 74: 45-54.
41. Balasa B, Deng C, Lee J, Christadoss P, Sarvetnick N. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J Immunol 1998; 161: 2856-62.
42. Shenoy M, Baron S, Wu B, Goluszko E, Christadoss P. IFN-alpha treatment suppresses the development of experimental autoimmune myasthenia gravis. J Immunol 1995; 154: 6203-8.
43. Bolay H, Karabudak R, Aybay C, Candemir H, Varli K, Imir T, et al. Alpha interferon treatment in myasthenia gravis: effects on natural killer cell activity. J Neuroimmunol 1998; 82: 109-15.
44. Albuquerque EX, Rash IE, Mayer RF. An electrophysiological and morphological study of the neuromuscular junction in patients with myasthenia gravis. Exp Neurol 1976; 51: 536-63.
45. Desmedt JE. The neuromuscular disorder in myasthenia gravis. 1. Electrical and mechanical response to nerve stimulation in hand muscles. In: Desmedt JE, ed. New Developments in Electromyography and Clinical Neurophysiology. Basel: Karger; 1973: 241-304.
46. Ekstedt J, Stalberg E. Myasthenia gravis. Diagnostic aspects by a new electrophysiological method (in Swedish). Opusc Med 1967; 12: 73-6.